People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for ...

For investors in Novo Nordisk (NYSE: NVO), 2025 has been a challenging year. After reaching a 52-week high of over $112, the ...

The company recently announced the acquisition of a biotech with an innovative cancer treatment. Johnson & Johnson had strong ...

Though healthcare stocks have been much more measured this year, there are bright spots there as well. The medical-device maker Medtronic (MDT) closed at its highest price since May 12, 2022, after ...

Operated by the federal government, TrumpRx aims to reduce the amount that Americans — including Medicaid patients — pay for ...

Zentalis Pharmaceuticals, Inc. focuses on developing azenosertib with a pivotal Denali Phase 2 trial underway. Learn more ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

The drugmaker said it has started selling higher doses of the injectable treatment for $349 a month to patients paying the ...

The cash price for popular weight-loss medication Wegovy is dropping by 30% in U.S. on Monday, according to Novo Nordisk.

Wegovy and Ozempic will be available in the lowest doses for $199 a month for two months, after which the drugs will be ...